Series A+ · Biotech
Dioseve: Series A+
Develops iPS cell-derived co-culture technology to improve oocyte maturation and reduce IVF treatment burden
Funding history
Series A+ · This round$7M
Loading rounds…
Develops iPS cell-derived co-culture technology to improve oocyte maturation and reduce IVF treatment burden